Medical plastic being broken down by a resistant strain of bacteria
A dangerous superbug, Pseudomonas aeruginosa, has been found to digest plastic, specifically polycaprolactone (PCL), which is used in various medical devices such as sutures, stents, implants, wound dressings, drug-delivery patches, and surgical mesh. This discovery, published in Cell Reports, challenges the widely held belief that pathogens cannot degrade medical plastics.
The bacterium produces an enzyme called Pap1 that enables it to break down PCL. By degrading the plastic, it not only survives but also uses the resulting fragments to strengthen its biofilms, which makes these bacterial communities more resistant to antibiotics and immune system attacks.
This ability has important implications for hospital-acquired infections (HAIs). Since P. aeruginosa is already a notorious pathogen with high antibiotic resistance, its capacity to utilize plastics found on medical devices creates a new challenge. The strengthened biofilms on degradable plastics can help it persist on devices longer, increasing the risk of infection.
The implications stretch beyond one material, as similar enzymes have been identified in other pathogens, suggesting that other plastics could also be vulnerable to microbial attack. This raises concerns that other widely used medical materials made from polyethylene terephthalate or polyurethane may be at risk.
Infection control experts may need to reconsider how they monitor hospital environments. There is a need to screen pathogens for these enzymes, particularly in unexplained prolonged outbreaks. McCarthy, the lead researcher, suggests focusing on plastics harder for microbes to digest for patient safety.
The high antibiotic resistance and biofilm-related wound healing delays caused by P. aeruginosa also compound these issues in clinical care. This discovery represents a meaningful shift in understanding the persistence and virulence of hospital pathogens linked to plastic medical devices. It demands urgent attention to improve patient safety and medical device management practices.
References: 1. McCarthy et al. (2022). Pseudomonas aeruginosa degrades polycaprolactone via the enzyme Pap1. Cell Reports. 2. Centers for Disease Control and Prevention. Antibiotic/Antimicrobial Resistance Threats in the United States, 2019.
This article is based on a summary of research findings and does not contain original research.
- The research published in Cell Reports indicates that the bacterium Pseudomonas aeruginosa can degrade medical plastics like polycaprolactone (PCL), which are commonly used in medical devices, using an enzyme called Pap1.
- The discovery of the enzyme Pap1 in Pseudomonas aeruginosa by McCarthy's team can have far-reaching implications in digital health and health-and-wellness, as similar enzymes have been found in other pathogens, suggesting that other plastics might also be susceptible to microbial attacks, posing potential threats to hospital-acquired infections and medical devices management practices.
